Caveolin-1 mediated expression and secretion of Kallikrein 6 in colon cancer cells

Rebecca S. Henkhaus, Upal Kunal Basu Roy, Dora Cavallo-Medved, Bonnie F. Sloane, Eugene W. Gerner, Natalia Ignatenko

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Kallikreins are secreted proteases that may play a functional role and/or serve as a serum biomarker for the presence or progression of certain types of cancers. Kallikrein 6 (KLK6) has been shown to be upregulated in several types of cancers, including colon. The aims of this study were to elucidate pathways that influence KLK6 gene expression and KLK6 protein secretion in the HCT116 human colon cancer cells. Our data indicate a central role for caveolin-1 (CAV-1), the main structural protein of caveolae, in both KLK6 gene expression and protein secretion. Sucrose gradient subcellular fractionation reveals that CAV-1 and KLK6 colocalize to lipid raft domains in the plasma membrane of HCT116 cells. Furthermore, we show that CAV-1, although it does not directly interact with the KLK6 molecule, enhances KLK6 secretion from the cells. Deactivation of CAV-1, through SRC-mediated phosphorylation, decreased KLK6 secretion. We also demonstrate that, in colon cancer cells, CAV-1 increased the amount of phosphorylated AKT in cells by inhibiting the activity of the AKT-negative regulators PP1 and PP2A. This study demonstrates that proteins such as CAV-1 and AKT, which are known to be altered in colon cancer, affect KLK6 expression and KLK6 secretion.

Original languageEnglish (US)
Pages (from-to)140-148
Number of pages9
JournalNeoplasia
Volume10
Issue number2
DOIs
StatePublished - Feb 2008

Fingerprint

Caveolin 1
Kallikreins
Colonic Neoplasms
Proteins
HCT116 Cells
Gene Expression
Caveolae
Sucrose
Peptide Hydrolases
Biomarkers
Phosphorylation
Cell Membrane

ASJC Scopus subject areas

  • Cancer Research

Cite this

Henkhaus, R. S., Roy, U. K. B., Cavallo-Medved, D., Sloane, B. F., Gerner, E. W., & Ignatenko, N. (2008). Caveolin-1 mediated expression and secretion of Kallikrein 6 in colon cancer cells. Neoplasia, 10(2), 140-148. https://doi.org/10.1593/neo.07817

Caveolin-1 mediated expression and secretion of Kallikrein 6 in colon cancer cells. / Henkhaus, Rebecca S.; Roy, Upal Kunal Basu; Cavallo-Medved, Dora; Sloane, Bonnie F.; Gerner, Eugene W.; Ignatenko, Natalia.

In: Neoplasia, Vol. 10, No. 2, 02.2008, p. 140-148.

Research output: Contribution to journalArticle

Henkhaus, RS, Roy, UKB, Cavallo-Medved, D, Sloane, BF, Gerner, EW & Ignatenko, N 2008, 'Caveolin-1 mediated expression and secretion of Kallikrein 6 in colon cancer cells', Neoplasia, vol. 10, no. 2, pp. 140-148. https://doi.org/10.1593/neo.07817
Henkhaus, Rebecca S. ; Roy, Upal Kunal Basu ; Cavallo-Medved, Dora ; Sloane, Bonnie F. ; Gerner, Eugene W. ; Ignatenko, Natalia. / Caveolin-1 mediated expression and secretion of Kallikrein 6 in colon cancer cells. In: Neoplasia. 2008 ; Vol. 10, No. 2. pp. 140-148.
@article{698936482b6d4533902c86917985f121,
title = "Caveolin-1 mediated expression and secretion of Kallikrein 6 in colon cancer cells",
abstract = "Kallikreins are secreted proteases that may play a functional role and/or serve as a serum biomarker for the presence or progression of certain types of cancers. Kallikrein 6 (KLK6) has been shown to be upregulated in several types of cancers, including colon. The aims of this study were to elucidate pathways that influence KLK6 gene expression and KLK6 protein secretion in the HCT116 human colon cancer cells. Our data indicate a central role for caveolin-1 (CAV-1), the main structural protein of caveolae, in both KLK6 gene expression and protein secretion. Sucrose gradient subcellular fractionation reveals that CAV-1 and KLK6 colocalize to lipid raft domains in the plasma membrane of HCT116 cells. Furthermore, we show that CAV-1, although it does not directly interact with the KLK6 molecule, enhances KLK6 secretion from the cells. Deactivation of CAV-1, through SRC-mediated phosphorylation, decreased KLK6 secretion. We also demonstrate that, in colon cancer cells, CAV-1 increased the amount of phosphorylated AKT in cells by inhibiting the activity of the AKT-negative regulators PP1 and PP2A. This study demonstrates that proteins such as CAV-1 and AKT, which are known to be altered in colon cancer, affect KLK6 expression and KLK6 secretion.",
author = "Henkhaus, {Rebecca S.} and Roy, {Upal Kunal Basu} and Dora Cavallo-Medved and Sloane, {Bonnie F.} and Gerner, {Eugene W.} and Natalia Ignatenko",
year = "2008",
month = "2",
doi = "10.1593/neo.07817",
language = "English (US)",
volume = "10",
pages = "140--148",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Caveolin-1 mediated expression and secretion of Kallikrein 6 in colon cancer cells

AU - Henkhaus, Rebecca S.

AU - Roy, Upal Kunal Basu

AU - Cavallo-Medved, Dora

AU - Sloane, Bonnie F.

AU - Gerner, Eugene W.

AU - Ignatenko, Natalia

PY - 2008/2

Y1 - 2008/2

N2 - Kallikreins are secreted proteases that may play a functional role and/or serve as a serum biomarker for the presence or progression of certain types of cancers. Kallikrein 6 (KLK6) has been shown to be upregulated in several types of cancers, including colon. The aims of this study were to elucidate pathways that influence KLK6 gene expression and KLK6 protein secretion in the HCT116 human colon cancer cells. Our data indicate a central role for caveolin-1 (CAV-1), the main structural protein of caveolae, in both KLK6 gene expression and protein secretion. Sucrose gradient subcellular fractionation reveals that CAV-1 and KLK6 colocalize to lipid raft domains in the plasma membrane of HCT116 cells. Furthermore, we show that CAV-1, although it does not directly interact with the KLK6 molecule, enhances KLK6 secretion from the cells. Deactivation of CAV-1, through SRC-mediated phosphorylation, decreased KLK6 secretion. We also demonstrate that, in colon cancer cells, CAV-1 increased the amount of phosphorylated AKT in cells by inhibiting the activity of the AKT-negative regulators PP1 and PP2A. This study demonstrates that proteins such as CAV-1 and AKT, which are known to be altered in colon cancer, affect KLK6 expression and KLK6 secretion.

AB - Kallikreins are secreted proteases that may play a functional role and/or serve as a serum biomarker for the presence or progression of certain types of cancers. Kallikrein 6 (KLK6) has been shown to be upregulated in several types of cancers, including colon. The aims of this study were to elucidate pathways that influence KLK6 gene expression and KLK6 protein secretion in the HCT116 human colon cancer cells. Our data indicate a central role for caveolin-1 (CAV-1), the main structural protein of caveolae, in both KLK6 gene expression and protein secretion. Sucrose gradient subcellular fractionation reveals that CAV-1 and KLK6 colocalize to lipid raft domains in the plasma membrane of HCT116 cells. Furthermore, we show that CAV-1, although it does not directly interact with the KLK6 molecule, enhances KLK6 secretion from the cells. Deactivation of CAV-1, through SRC-mediated phosphorylation, decreased KLK6 secretion. We also demonstrate that, in colon cancer cells, CAV-1 increased the amount of phosphorylated AKT in cells by inhibiting the activity of the AKT-negative regulators PP1 and PP2A. This study demonstrates that proteins such as CAV-1 and AKT, which are known to be altered in colon cancer, affect KLK6 expression and KLK6 secretion.

UR - http://www.scopus.com/inward/record.url?scp=39049089569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049089569&partnerID=8YFLogxK

U2 - 10.1593/neo.07817

DO - 10.1593/neo.07817

M3 - Article

C2 - 18283336

AN - SCOPUS:39049089569

VL - 10

SP - 140

EP - 148

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 2

ER -